XVIPF (Xvivo Perfusion AB) Total Liabilities: $32.16 Mil (As of Mar. 2026)

What is Xvivo Perfusion AB Total Liabilities?

Xvivo Perfusion AB XVIPF -1.32% 91 Total Liabilities is $32.16 Mil as of Mar. 2026. GuruFocus rates XVIPF with a GF Score™ of 91/100 and a GF Value™ of $42.07 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Xvivo Perfusion AB's Total Liabilities for the quarter that ended in Mar. 2026 was $32.16 Mil.

Xvivo Perfusion AB's quarterly Total Liabilities declined from Sep. 2025 ($30.24 Mil) to Dec. 2025 ($28.05 Mil) but then increased from Dec. 2025 ($28.05 Mil) to Mar. 2026 ($32.16 Mil).

Xvivo Perfusion AB's annual Total Liabilities declined from Dec. 2023 ($24.43 Mil) to Dec. 2024 ($22.39 Mil) but then increased from Dec. 2024 ($22.39 Mil) to Dec. 2025 ($28.05 Mil).

Xvivo Perfusion AB Total Liabilities Related Terms

Xvivo Perfusion AB Total Liabilities Historical Data

* Premium members only.

The historical data trend for Xvivo Perfusion AB's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xvivo Perfusion AB Total Liabilities Chart

Xvivo Perfusion AB Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Total Liabilities

Get a 7-Day Free Trial

28.29

29.19

24.43

22.39

28.05

Xvivo Perfusion AB Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Total Liabilities	Get a 7-Day Free Trial															20.00	30.95	30.24	28.05	32.16

91GF Score

Xvivo Perfusion AB XVIPF

Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Xvivo Perfusion AB Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Xvivo Perfusion AB's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	12.845	+	(12.177	+	3.025
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	28.05

Total Liabilities	=	Total Assets (A: Dec. 2025 )	-	Total Equity (A: Dec. 2025 )
	=	255.459	-	227.413
	=	28.05

Xvivo Perfusion AB's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	17.212	+	(11.948	+	2.996
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	32.16

Total Liabilities	=	Total Assets (Q: Mar. 2026 )	-	Total Equity (Q: Mar. 2026 )
	=	264.991	-	232.835
	=	32.16

Frequently Asked Questions Learn more about Total Liabilities →

What does a Total Liabilities of $32.16 Mil mean?

Xvivo Perfusion AB (XVIPF) has a Total Liabilities of $32.16 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Xvivo Perfusion AB and its competitors.

Is Xvivo Perfusion AB's Total Liabilities too high?

Xvivo Perfusion AB's current Total Liabilities is $32.16 Mil. Overall, Xvivo Perfusion AB has a GF Score™ of 91/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Xvivo Perfusion AB's Total Liabilities compare to ABT and SYK?

Xvivo Perfusion AB's Total Liabilities of $32.16 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Total Liabilities for a Medical Devices & Instruments company?

A good Total Liabilities depends on the Medical Devices & Instruments industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Total Liabilities mean?

A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Xvivo Perfusion AB and its competitors. Xvivo Perfusion AB's current Total Liabilities is $32.16 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Xvivo Perfusion AB stock overvalued right now?

Based on GuruFocus' analysis, Xvivo Perfusion AB (XVIPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $42.07, compared to a current price of $29.00 — trading 31.1% below its estimated fair value. The current Total Liabilities is $32.16 Mil. Xvivo Perfusion AB's overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Total Liabilities calculated?

Total Liabilities is calculated from a company's financial statements. For Xvivo Perfusion AB (XVIPF), the current Total Liabilities is $32.16 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xvivo Perfusion AB (XVIPF) Overvalued in 2026?

Based on GuruFocus' analysis, Xvivo Perfusion AB stock appears to be undervalued. The current stock price of $29.00 is trading 31.1% below its estimated GF Value™ of $42.07. GuruFocus considers Xvivo Perfusion AB to be Significantly Undervalued.

Key valuation signals for XVIPF:

Total Liabilities: $32.16 Mil
GF Value™: $42.07 vs. price of $29.00 (31.1% below fair value)
GF Score™: 91/100 with 2 warning signs

No single metric tells the full story. See the XVIPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xvivo Perfusion AB Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies OSTO:MCAP OSTO:VITR OSTO:NOLA B OSTO:CEVI OSTO:DVYSR OSTO:BICO OSTO:PAX OSTO:CRAD B OSTO:SEDANA OSTO:EPIS B ABT SYK MDT BSX EW XTER:SHL DXCM GEHC SZSE:300760 XAMS:PHIA

Other Exchanges XVIVO:Sweden XVIVOs:UK 0RKL:UK 3XV:Germany

Address Gemenskapens gata 9, Molndal, SWE, SE-431 53

Website https://www.xvivoperfusion.com

Xvivo Perfusion AB is a medical technology company dedicated to extending the life of organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments, namely Thoracic: sales of lung and heart transplant products; Abdominal: sales of liver and kidney transplant products and perfusion services; and Services: revenue from the sale of services related to organ recovery, as well as digital products for communication and workflow management at transplantation clinics. The majority of revenue is derived from the Thoracic segment, and geographically, the majority is from the United States.

91GF Score

Get the complete analysis for XVIPF

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$29.00

Price

$42.07

GF Value

View XVIPF Analysis

See Total Liabilities data for all stocks →